Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | BTN3A1 | O00481 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ENO1 | P06733 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 5/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL681950 | 0.88 | PRKCA (0.46) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL13686395 | 0.87 | PRKCA (0.39) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL11645846 | 0.87 | PRKCA (0.48) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL13064109 | 0.84 | PRKCA (0.37) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL10874209 | 0.82 | BTN3A1 (0.41) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL15472935 | 0.81 | PRKCA (0.42) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL434232 | 0.81 | PRKCA (0.42) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL807413 | 0.81 | PRKCA (0.42) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL15424775 | 0.79 | PRKCA (0.41) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL8716409 | 0.79 | PRKCA (0.41) | PRKCABTN3A1ALDH1A1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0049499-B1 | CEPHALOSPORIN DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES FOR THEIR PREPARATION | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1986-01-29 | — | — | EP | claimed |
| US-4412070-A | ANTIBIOTICS | HOFFMANN-LA ROCHE INC. (US) | 1983-10-25 | — | — | US | claimed |
| EP-0049499-A2 | Cephalosporin derivatives, process for their preparation, pharmaceutical compositions containing them and intermediates for their preparation | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-04-14 | — | — | EP | claimed |
| CN-119097698-A | Inhibitors of mevalonate pathway as efficient vaccine adjuvants | 清华大学 | 2024-12-10 | — | — | CN | disclosed |
| CN-114848656-B | Inhibitors of mevalonate pathway as efficient vaccine adjuvants | 清华大学 | 2024-09-27 | — | — | CN | disclosed |
| CN-117986251-A | 4H-pyrrolo [3,2-c ] pyridin-4-one compounds | 拜耳股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117946100-A | 4H-pyrrolo [3,2-c ] pyridin-4-one compounds | 拜耳股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-114127064-B | 4H-pyrrolo [3,2-c ] pyridin-4-one compounds | 拜耳股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-115073421-B | Carboxylic aromatic amides as bradykinin B1 receptor antagonists | 拜耳制药股份公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-111225672-B | Mevalonate pathway inhibitor and pharmaceutical composition thereof | 清华大学 | 2023-09-29 | — | — | CN | disclosed |
| CN-115137726-A | Carboxylic acid aromatic amides as bradykinin B1 receptor antagonists | 拜耳制药股份公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-107406417-B | 4H-pyrrolo [3,2-c ] pyridin-4-one derivatives | 拜耳制药股份公司 | 2020-06-09 | — | — | CN | disclosed |
| CN-111225672-A | Mevalonate pathway inhibitors and pharmaceutical compositions thereof | 清华大学 | 2020-06-02 | — | — | CN | disclosed |
| WO-2019076269-A1 | MEVALONIC ACID PATHWAY INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF | 清华大学 | 2019-04-25 | — | — | WO | disclosed |
| CN-103974964-B | Process for preparing beta-C-aryl glucosides | SCINOPHARM TAIWAN, LTD. (CN) | 2016-03-23 | — | — | CN | disclosed |
| US-20070072835-A1 | Method of preparing and use of prodrugs of betulinic acid derivatives | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-03-29 | — | — | US | disclosed |
| US-7091195-B2 | Method of preparing and use of prodrugs of betulinic acid derivatives | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2006-08-15 | — | — | US | disclosed |
| US-20030186945-A1 | Method of preparing and use of prodrugs of betulinic acid derivatives | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2003-10-02 | — | — | US | disclosed |
| US-6569842-B2 | Method of preparing and use of prodrugs of betulinic acid derivatives | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, THE | 2003-05-27 | — | — | US | disclosed |
| US-20020052352-A1 | Method of preparing and use of prodrugs of betulinic acid derivatives | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072835-A1 | Method of preparing and use of prodrugs of betulinic acid derivatives | BET1, PGGT1B, RABGGTB | PRKCA 1311/4885BTN3A1 672/4885ALDH1A1 2524/4885 |
| US-20030186945-A1 | Method of preparing and use of prodrugs of betulinic acid derivatives | BET1, PGGT1B, RABGGTB | PRKCA 1311/4885BTN3A1 672/4885ALDH1A1 2524/4885 |
| US-20020052352-A1 | Method of preparing and use of prodrugs of betulinic acid derivatives | BET1, PGGT1B, RABGGTB | PRKCA 1311/4885BTN3A1 672/4885ALDH1A1 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.